Anesth Pain Med.  2020 Jan;15(1):130. 10.17085/apm.2020.15.1.130.

IN REPLY: Sugammadex associated profound bradycardia and sustained hypotension

• Choi YJ
• Park JW
• Kim SH
• Jung KT

• KMID: 2500468
• DOI: http://doi.org/10.17085/apm.2020.15.1.130

Reference

Biro P., Paul G., Dahan A., Brull SJ. 2019. Proposal for a revised classification of the depth of neuromuscular block and suggestions for further development in neuromuscular monitoring. Anesth Analg. 128:1361–3. DOI: 10.1213/ANE.0000000000004065. PMID: 31094813.

Naguib M., Brull SJ., Kopman AF., Hunter JM., Fülesdi B., Arkes HR, et al. 2018. Consensus statement on perioperative use of neuromuscular monitoring. Anesth Analg. 127:71–80. DOI: 10.1213/ANE.0000000000002670. PMID: 29200077.

Dahl V., Pendeville PE., Hollmann MW., Heier T., Abels EA., Blobner M. 2009. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. Eur J Anaesthesiol. 26:874–84. DOI: 10.1097/EJA.0b013e32832c605b. PMID: 19455040.

Hunter JM., Naguib M. 2018. Sugammadex-induced bradycardia and asystole: how great is the risk? Br J Anaesth. 121:8–12. DOI: 10.1016/j.bja.2018.03.003. PMID: 29935599.

Kim YH. 2016. Sugammadex: watch out for new side effects. Korean J Anesthesiol. 69:427–8. DOI: 10.4097/kjae.2016.69.5.427. PMID: 27703621. PMCID: PMC5047976.